IP Library › Granted Patent US 11,674,138
Granted Patent B2
US 11,674,138 · App. 16/486,586 · Granted Jun 13, 2023

Methods of modulating expression of target nucleic acid sequences in a cell

Inventors: Suhani D. Vora (Cambridge, MA); Alejandro Chavez (New York, NY); Jing Cheng (Mountain View, CA); Benjamin W. Pruitt (Cambridge, MA)
Assignee: President and Fellows of Harvard College
C12N15/111C07K14/31C07K14/315C12N9/22C12N15/86C07K2319/33C12N2310/20C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,674,138
App. No.
16/486,586
Granted
Jun 13, 2023
Kind
B2
Abstract

The present disclosure provides methods and compositions of modulating expression of a target nucleic acid sequence in a cell. The method comprises introducing into the cell a nucleic acid sequence encoding a Cas9 fusion protein and a guide RNA, wherein the Cas9 fusion protein and the guide RNA are expressed and co-localize at a target site and modulate the expression of the target nucleic acid sequence.

Claims (31)

1. A method of activating expression of a target nucleic acid sequence in a eukaryotic cell comprising:

introducing into the cell a nucleic acid sequence encoding a Cas9 fusion protein and a guide RNA, wherein the Cas9 fusion protein comprises a nuclease-null Cas9 (dCas9) fused with an activation domain of VP64, an activation domain of p65, and an activation domain of RTA, wherein the activation domain of p65 comprises a protein sequence of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26, wherein the Cas9 fusion protein and the guide RNA are expressed and co-localize at a target site and activate the expression of the target nucleic acid sequence.

2. The method of claim 1 wherein the activation domains of VP64, p65 and RTA comprises a tripartite VP64-p65-RTA (VPR) fusion wherein each of the activation domains of VP64, p65 and RTA is truncated.

3. The method of claim 1 wherein a sequence encoding the Cas9 fusion protein is flanked by a promoter sequence at its 5′ end and a terminator sequence at its 3′ end wherein the promoter sequence is truncated.

4. The method of claim 3 wherein the terminator sequence is truncated.

5. The method of claim 4 wherein the terminator sequence comprises a short 17nt sNRP-1 (SEQ ID NO: 35), a 34nt dual sNRP-1 (SEQ ID NO: 36), a 50nt synthetic (SEQ ID NO: 37), or a 250 nt bGHR terminator.

6. The method of claim 1 wherein the activation domain of VP64 is a modified activation domain comprising protein sequence of SEQ ID NO: 17.

7. The method of claim 6 wherein the protein sequence is encoded by nucleic acid sequence of SEQ ID NO: 1.

8. The method of claim 1 wherein the activation domain of p65 is encoded by nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, respectively.

9. The method of claim 1 wherein the activation domain of RTA is a modified activation domain comprising RTA deletion protein.

10. The method of claim 9 wherein the RTA deletion protein comprises protein sequence of SEQ ID NO: 19, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32.

11. The method of claim 10 wherein the protein sequence is encoded by nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16, respectively.

12. The method of claim 1 wherein the activation domain of VP64 is a modified activation domain comprising protein sequence of SEQ ID NO: 17 and the activation domain of RTA is a modified activation domain comprising SEQ ID NO: 19, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32.

13. A method of activating expression of a target nucleic acid sequence in a eukaryotic cell comprising:

introducing into the cell a nucleic acid sequence encoding a Cas9 fusion protein and a guide RNA, wherein the Cas9 fusion protein comprises a nuclease-null Cas9 (dCas9) fused with an activation domain of VP64, an activation domain of p65, and an activation domain of RTA, wherein the activation domain of RTA comprises a protein sequence of SEQ ID NO: 19, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32,

wherein the Cas9 fusion protein and the guide RNA are expressed and co-localize at a target site and activate the expression of the target nucleic acid sequence.

14. The method of claim 13 wherein the protein sequence is encoded by nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16, respectively.

15. The method of claim 13 wherein the activation domains of VP64, p65 and RTA comprises a tripartite VP64-p65-RTA (VPR) fusion wherein each of the activation domains of VP64, p65 and RTA is truncated.

16. The method of claim 13 wherein a sequence encoding the Cas9 fusion protein is flanked by a promoter sequence at its 5′ end and a terminator sequence at its 3′ end wherein the promoter sequence is truncated.

17. The method of claim 16 wherein the terminator sequence is truncated.

18. The method of claim 16 wherein the terminator sequence comprises a short 17nt sNRP-1 (SEQ ID NO: 35), a 34nt dual sNRP-1 (SEQ ID NO: 36), a 50nt synthetic (SEQ ID NO: 37), or a 250 nt bGHR terminator.

19. The method of claim 13 wherein the activation domain of VP64 is a modified activation domain comprising protein sequence of SEQ ID NO: 17.

20. The method of claim 19 wherein the protein sequence is encoded by nucleic acid sequence of SEQ ID NO: 1.

21. The method of claim 13 wherein the activation domain of p65 is a modified activation domain comprising p65 deletion protein.

22. The method of claim 21 wherein the p65 deletion protein comprises protein sequence of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.

23. The method of claim 13 wherein the activation domain of p65 is encoded by nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, respectively.

24. The method of claim 13 wherein the activation domain of VP64 is a modified activation domain comprising protein sequence of SEQ ID NO: 17 and wherein the activation domain of p65 is a modified activation domain comprising protein sequence of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.

25. The method of claim 1 wherein the nucleic acid sequence encoding a Cas9 fusion protein and a guide RNA is within an AAV which is introduce into the eukaryotic cell.

26. The method of claim 15 wherein the nucleic acid sequence encoding a Cas9 fusion protein and a guide RNA is within an AAV which is introduce into the eukaryotic cell.

27. The method of claim 1 wherein the Cas9 is spCas9, St1Cas9 or SaCas9.

28. The method of claim 13 wherein the Cas9 is spCas9, St1Cas9 or SaCas9.

Continuity (2)
Provisional Application 62470538 · Mar 13, 2017
Related Publication 20190376060A1 · Dec 12, 2019